Dose‐response studies of quazepam

  title={Dose‐response studies of quazepam},
  author={Anthony Kales and Martin B. Scharf and Edward O. Bixler and Paula K. Schweitzer and Judith A. Jacoby and Constantin R Soldates},
  journal={Clinical Pharmacology \& Therapeutics},
Quazepam, an investigational benzodiazepine, was evaluated in doses of 7.5, 15, and 30 mg in a 12‐night protocol including four nights of drug trial. All three doses were effective in inducing and maintaining sleep, with the highest degree of effectiveness after the first drug night. Carry‐over effectiveness, which was seen after withdrawal of all three doses, persisted throughout the withdrawal period after the 30‐mg dose. Quazepam's effects during both drug use and withdrawal appeared to be… 
Quazepam and flurazepam: Long‐term use and extended withdrawal
The data suggest that the optimal dose of quazepam is 15 mg, and some loss of effectiveness was noted during long‐term use of both doses of quzepam and, to a lesser extent, of flurazepams.
Quazepam and temazepam: Effects of short‐ and intermediate‐term use and withdrawal
Although temazepam was effective for maintaining sleep with short‐term use, there was rapid development of tolerance for this effect with intermediate‐ term use, and quazEPam had carryover effectiveness.
Quazepam: Hypnotic Efficacy and Side Effects
  • A. Kales
  • Medicine, Psychology
  • 1990
Quazepam is a benzodiazepine hypnotic that can be useful in the adjunctive pharmacologic treatment of insomnia and is more effective with short‐term use, and with continued use it maintains its efficacy in contrast to both of these drugs which show rapid development of tolerance.
Comparison of short and long half‐life benzodiazepine hypnotics: Triazolam and quazepam
The 0.25 mg dose of triazolam, which is being prescribed increasingly, has a profile of side effects that is similar to that of the 0.5 mg dose, and is associated with sleep and mood disturbances whereas quazepam exerted carryover effectiveness.
Multiple‐dose quazepam kinetics
These kinetic profiles may explain the clinical hypnotic effect of quazepam—rapid induction of sleep and long duration of clinical action without appreciable rebound insomnia.
Quazepam kinetics in the elderly
Comparison of these data with reported kinetic data in young subjects shows that t½βs of quazepam and 2‐oxoquzepam increased only slightly or not at all with age, but that the t½ β of N‐desalkyl‐2‐oxquazep am in the elderly was more than twice that in youngSubjects.
Reintroduction of quazepam: an update on comparative hypnotic and adverse effects.
  • N. Moniri
  • Psychology, Biology
    International clinical psychopharmacology
  • 2019
The purpose of this review is to provide an update on distinguishing features of quazepam with regard to its pharmacology, pharmacokinetics, sleep efficacy and potential adverse effects compared to other agents used for insomnia.
Recent advances in the clinical pharmacology of benzodiazepines part I: Pharmacokinetics
Pharmacokinetic studies dealing with absorption, metabolism and elimination after acute and chronic administration demonstrate that the onset and duration of action of BZD after single oral doses depend largely on absorption rate and the rate and extent of distribution.
Withdrawal Reactions after Stopping Hypnotics in Patients with Insomnia
Withdrawal is usually uneventful with these drugs, and both can be used as transitional therapies in the more difficult task of discontinuing benzodiazepines in long term users, but dosage considerations are important with all hypnotics and treatment should be at the lowest effective dose and for the shortest duration.
Rebound and withdrawal with benzodiazepine and non-benzodiazepine hypnotic medication
The purpose of this chapter is to review briefly the clinical problems that can be encountered when discontinuing hypnotic drugs within the normal therapeutic context.


Sleep laboratory studies of flurazepam: A model for evaluating hypnotic drugs
The results from six separate evaluations of flurazepam 30 mg in the sleep laboratory were combined to determine the effectiveness of the drug in inducing and maintaining sleep and its effects on
Quazepam, A New Benzodiazepine Hypnotic: Intermediate‐Term Sleep Laboratory Evaluation
Data regarding long-term safety or tolerance of the drug suggest that quazepam is well tolerated and that its pharmacological effects are similar to those of other benzodiazepines.
Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines.
Rebound insomnia occurred following withdrawal of triazolam, nitrazepam, and flunitsepam after they had been given in only single, nightly doses for short periods, attributed to the short and intermediate half-lives of these drugs.
Blood level profile in man following chronic oral administration of flurazepam hydrochloride.
The blood level profile of flurazepam and its major metabolites was determined in man following the oral administration of 30 mg. daily for 2 weeks. The levels of the intact drug were below the
Clinical Evaluation of Hypnotic Drugs: Contributions from Sleep Laboratory Studies
Several basic principles derived from sleep laboratory findings have been incorporated into both the clinical trials and sleep laboratory evaluations recommended in the new FDA Guidelines for the Clinical Evaluation of Hypnotic Drugs.
Multiple Comparisons among Means
Abstract Methods for constructing simultaneous confidence intervals for all possible linear contrasts among several means of normally distributed variables have been given by Scheffe and Tukey. In
The Government Printing Office
• The official journals of government are produced at their 1.5 million square foot plant, the largest industrial facility in the District. There are significant issues of outdated plant and
Methodology of sleep laboratory drug evaluations
  • Hypnotics: Methods of development and evaluation
  • 1975
dioimmunoassay of flurazepam in human plas
  • J Pharm Sci
  • 1980
Guidelines for the clinical evaluation of hypnotic drugs
  • J Pharm Sci
  • 1980